Cellectar opened its GMP compliant radiopharmaceutical manufacturing facility in December, 2007. This facility, consisting of approximately 16,000 ft², contains offices, laboratories, a radiopharmaceutical research lab, a GMP radiopharmaceutical manufacturing suite and a GMP analytical laboratory for product release. In August 2008, Cellectar began manufacturing to validated GMP standards, and as a result, maintains the ability to be completely independent in radiopharmaceutical research, development and manufacturing.  Our facility is of sufficient capacity to deliver all drug product required for each phase of our clinical trials, and has additional square footage allocated for expansion.

Bringing manufacturing capability in-house also provides Cellectar with the opportunity to consider in-licensing arrangements with prospective companies or academic partners. Interested parties should contact Neal Sandy, COO at info@cellectar.com.